Nifty
Sensex
:
:
11050.25
37388.66
244.70 (2.26%)
835.06 (2.28%)

Pharmaceuticals & Drugs - Global

Rating :
67/99

BSE: 532296 | NSE: GLENMARK

482.55
25-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  459.20
  •  485.00
  •  458.05
  •  454.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2923805
  •  13866.91
  •  573.05
  •  161.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,623.08
  • 14.80
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,380.47
  • 0.52%
  • 2.16

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.62%
  • 2.02%
  • 16.59%
  • FII
  • DII
  • Others
  • 23.4%
  • 2.36%
  • 9.01%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.69
  • 7.07
  • 5.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 3.39
  • 1.00

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.53
  • 0.87
  • -1.17

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.76
  • 19.08
  • 15.63

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.97
  • 4.16
  • 2.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.37
  • 12.61
  • 9.90

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
2,344.79
2,322.88
0.94%
2,767.49
2,563.47
7.96%
2,735.56
2,555.05
7.06%
2,815.04
2,581.33
9.05%
Expenses
1,866.72
1,980.97
-5.77%
2,301.80
2,199.34
4.66%
2,295.49
2,120.37
8.26%
2,364.63
2,141.23
10.43%
EBITDA
478.07
341.91
39.82%
465.69
364.13
27.89%
440.08
434.68
1.24%
450.41
440.11
2.34%
EBIDTM
20.39%
14.72%
14.01%
14.20%
16.09%
17.01%
16.00%
17.05%
Other Income
58.51
1.67
3,403.59%
44.14
39.06
13.01%
32.96
-109.02
-
80.83
139.88
-42.21%
Interest
93.74
93.02
0.77%
98.47
81.91
20.22%
96.06
88.53
8.51%
89.77
85.13
5.45%
Depreciation
113.22
90.73
24.79%
126.28
80.97
55.96%
106.00
83.10
27.56%
94.16
82.45
14.20%
PBT
357.61
159.83
123.74%
317.96
240.31
32.31%
270.98
154.03
75.93%
347.30
579.59
-40.08%
Tax
103.57
50.55
104.89%
97.65
78.65
24.16%
80.14
37.69
112.63%
91.76
165.59
-44.59%
PAT
254.04
109.28
132.47%
220.31
161.66
36.28%
190.84
116.34
64.04%
255.54
414.00
-38.28%
PATM
10.83%
4.70%
7.11%
6.31%
6.98%
4.55%
9.08%
16.04%
EPS
9.00
3.87
132.56%
7.81
5.73
36.30%
6.76
4.12
64.08%
9.06
14.67
-38.24%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
10,662.88
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
Net Sales Growth
6.39%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
 
Cost Of Goods Sold
7,364.96
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
Gross Profit
3,297.92
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
GP Margin
30.93%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
Total Expenditure
8,828.64
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
Power & Fuel Cost
-
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
% Of Sales
-
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
Employee Cost
-
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
% Of Sales
-
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
Manufacturing Exp.
-
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
% Of Sales
-
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
General & Admin Exp.
-
1,168.32
625.20
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
% Of Sales
-
10.98%
6.34%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
Selling & Distn. Exp.
-
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
% Of Sales
-
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
Miscellaneous Exp.
-
47.19
299.19
314.55
88.52
38.82
38.48
228.40
33.61
0.00
0.00
% Of Sales
-
0.44%
3.03%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
EBITDA
1,834.25
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
EBITDA Margin
17.20%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
Other Income
216.44
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
Interest
378.04
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
Depreciation
439.66
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
PBT
1,293.85
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
Tax
373.12
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
Tax Rate
28.84%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
PAT
920.73
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
PAT before Minority Interest
920.58
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
Minority Interest
-0.15
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
PAT Margin
8.63%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
PAT Growth
14.91%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
 
EPS
32.63
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31
16.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
Share Capital
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
Total Reserves
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
Non-Current Liabilities
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
Unsecured Loans
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
Current Liabilities
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
Trade Payables
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
Other Current Liabilities
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
Short Term Borrowings
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
Short Term Provisions
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
Total Liabilities
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
Net Block
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
Gross Block
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
Accumulated Depreciation
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
Non Current Assets
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
Capital Work in Progress
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
Non Current Investment
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
123.97
109.57
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
Other Non Current Assets
26.49
0.59
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
Current Assets
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
Sundry Debtors
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
Cash & Bank
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
Other Current Assets
1,147.78
765.22
810.78
683.39
986.77
774.38
872.81
635.91
593.95
465.11
Short Term Loans & Adv.
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
Net Current Assets
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
Total Assets
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
PBT
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
Adjustment
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
Changes in Working Capital
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
Cash after chg. in Working capital
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
Net Fixed Assets
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
Net Investments
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
Others
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
Cash from Financing Activity
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
Net Cash Inflow / Outflow
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
Opening Cash & Equivalents
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
Closing Cash & Equivalent
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
ROA
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
ROE
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
ROCE
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
Fixed Asset Turnover
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
Receivable days
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
Inventory Days
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
Payable days
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
Cash Conversion Cycle
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
Total Debt/Equity
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
Interest Cover
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00

News Update:


  • Glenmark Pharmaceuticals reports 2-fold jump in Q1 consolidated net profit
    17th Aug 2020, 11:21 AM

    Total consolidated income of the company increased by 3.39% at Rs 2,403.30 crore for Q1FY21

    Read More
  • Glenmark Pharma - Quarterly Results
    14th Aug 2020, 21:15 PM

    Read More
  • Glenmark to introduce higher strength of FabiFlu
    6th Aug 2020, 13:26 PM

    The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day

    Read More
  • Glenmark declares top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment
    23rd Jul 2020, 09:28 AM

    Favipiravir is a broad spectrum oral antiviral drug that selectively inhibits RNA-dependent RNA polymerase and the viral replication phase of SARS-CoV-2

    Read More
  • Glenmark Pharmaceuticals launches world’s first hypertension awareness symbol
    18th Jul 2020, 13:57 PM

    The symbol is developed in consultation with 50,000 leading doctors in the country, to raise awareness of the growing burden of hypertension

    Read More
  • Glenmark Pharmaceuticals cuts price of antiviral drug Favipiravir
    14th Jul 2020, 09:01 AM

    The company had launched the drug in June at a price of Rs 103 per tablet

    Read More
  • Glenmark commences post marketing surveillance study on FabiFlu
    13th Jul 2020, 11:35 AM

    Glenmark has announced a price reduction of 27% for FabiFlu

    Read More
  • Fitch affirms Glenmark Pharmaceuticals’ rating at ‘BB’ with stable outlook
    13th Jul 2020, 11:08 AM

    The agency has also affirmed Glenmark's $200 million 4.50% senior unsecured notes due 2021 at 'BB'

    Read More
  • Glenmark gets nod to launch favipiravir for treatment of COVID-19 patients
    20th Jun 2020, 08:53 AM

    The company has received the manufacturing and marketing approval from India's drug regulator

    Read More
  • Glenmark Pharmaceuticals’ arm receives USFDA’s approval for Fingolimod Capsules
    19th Jun 2020, 09:37 AM

    The Gilenya Capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.